Falcon Genomics, Inc. provides technologies for the diagnosis of cancer patients and the formulation of therapeutic strategies. The companyâs technology platform, the Cancer BioChip System (CBCS), identifies compounds that are required for anchorage-independent growth of patient cells. Its CBCS is used for cancer therapeutic target identification and validation. Falcon Genomics also provides CBCS services that limit the risks taken by its customers in adopting its technology. The company serves pharmaceutical companies and research institutions seeking a platform for the identification of cancer target
